For now, the PARTNER 3 trial durability analysis offers reassuring evidence of excellent midterm outcomes in low-risk patients. As TAVR continues to move into younger populations, understanding which durability pathways matter, and in whom, will be key to building effective lifetime valve strateg...

“These findings provide compelling justification for aficamten treatment as an appropriate alternative to current first-line treatment with metoprolol, to treat exercise intolerance in oHCM.”

[Sarcopenic obesity] is emerging as a systemic cardiometabolic phenotype linking ageing, impaired muscle biology, heart failure vulnerability and frailty. By enabling scalable opportunistic quantification of muscle mass from routine CMR, Sanghvi et al., provide proof of concept that deep learning...

Cardiologist, UT Southwestern Medical Center

These data support that simplifying medication regimens through a polypill approach can substantially improve both clinical and patient-centered outcomes in heart failure with reduced ejection fraction. Future trials are needed to evaluate long-term effects on mortality and morbidity and assess implementation strategies to inform the adoption of polypills for management of heart failure in diverse healthcare settings.